Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia
- PMID: 14985375
- PMCID: PMC1735695
- DOI: 10.1136/jmg.2003.012153
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia
Abstract
Primary erythermalgia is a rare autosomal dominant disease characterised by intermittent burning pain with redness and heat in the extremities. A previous study established the linkage of primary erythermalgia to a 7.94 cM interval on chromosome 2q, but the causative gene was not identified. We performed linkage analysis in a Chinese family with primary erythermalgia, and screened the mutations in the two candidate genes, SCN9A and GCA, in the family and a sporadic patient. Linkage analysis yielded a maximum lod score of 2.11 for both markers D2S2370 and D2S2330. Based on critical recombination events in two patients in the family, we further limited the genetic region to 5.98 cM between D2S2370 and D2S2345. We then identified two missense mutations in SCN9A in the family (T2573A) and the sporadic patient (T2543C). Our data suggest that mutations in SCN9A cause primary erythermalgia. SCN9A, encoding a voltage-gated sodium channel alpha subunit predominantly expressed in sensory and sympathetic neurones, may play an important role in nociception and vasomotor regulation.
Similar articles
-
SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels.J Invest Dermatol. 2005 Jun;124(6):1333-8. doi: 10.1111/j.0022-202X.2005.23737.x. J Invest Dermatol. 2005. PMID: 15955112
-
Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.Clin Exp Dermatol. 2009 Dec;34(8):e640-2. doi: 10.1111/j.1365-2230.2009.03355.x. Epub 2009 Jun 22. Clin Exp Dermatol. 2009. PMID: 19549232
-
Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A.Arch Dermatol. 2008 Mar;144(3):320-4. doi: 10.1001/archderm.144.3.320. Arch Dermatol. 2008. PMID: 18347287
-
[From gene to disease; primary erythermalgia--a neuropathic disease as a consequence of mutations in a sodium pump gene].Ned Tijdschr Geneeskd. 2006 Jan 28;150(4):194-6. Ned Tijdschr Geneeskd. 2006. PMID: 16471234 Review. Dutch.
-
Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation.Vasc Med. 2012 Feb;17(1):44-9. doi: 10.1177/1358863X11422584. Epub 2011 Oct 27. Vasc Med. 2012. PMID: 22033523 Review.
Cited by
-
Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain.J Biol Chem. 2016 Jul 1;291(27):13974-13986. doi: 10.1074/jbc.M116.725978. Epub 2016 Apr 22. J Biol Chem. 2016. PMID: 27129258 Free PMC article.
-
Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula.Toxins (Basel). 2015 Jun 30;7(7):2494-513. doi: 10.3390/toxins7072494. Toxins (Basel). 2015. PMID: 26134258 Free PMC article.
-
Genistein inhibits voltage-gated sodium currents in SCG neurons through protein tyrosine kinase-dependent and kinase-independent mechanisms.Pflugers Arch. 2008 Aug;456(5):857-66. doi: 10.1007/s00424-008-0444-2. Epub 2008 Jan 29. Pflugers Arch. 2008. PMID: 18228037
-
Erythema and burning pain in the vulva: a possible phenotype of erythromelalgia.Case Rep Med. 2011;2011:374167. doi: 10.1155/2011/374167. Epub 2011 Apr 13. Case Rep Med. 2011. PMID: 21541228 Free PMC article.
-
Selective Closed-State Nav1.7 Blocker JZTX-34 Exhibits Analgesic Effects against Pain.Toxins (Basel). 2018 Feb 2;10(2):64. doi: 10.3390/toxins10020064. Toxins (Basel). 2018. PMID: 29393892 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases